TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12544672

Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream (32 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 80
Study: 10972216

Group type: EXPERIMENTAL
Intervention: Routine stenting
Number of subjects: 280

Group type: COMPARATOR
Intervention: No routine stenting
Number of subjects: 280
Study: 8928537

Group type: EXPERIMENTAL
Intervention: Patient education program (4 sessions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 36
Study: 1740930

Group type: EXPERIMENTAL
Intervention: Unlimited intravenous fluids (1294 +/- 58 ml)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fluid restriction (500 ml or less, 485 +/- 2 ml)
Number of subjects: 113
Study: 6408663

Group type: EXPERIMENTAL
Intervention: 150 mg/day amitriptyline (AT)
Number of subjects: 74
Study: 31646974

Group type: EXPERIMENTAL
Intervention: Paranasal air suction (three intermittent 10 sec suctions with 10 sec intervals)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo air suction (no paranasal air suction)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Paranasal air suction
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo air suction
Number of subjects: 56
Study: 29992370

Group type: EXPERIMENTAL
Intervention: 1.2 mg beloranib
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 1.8 mg beloranib
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 26482098

Group type: EXPERIMENTAL
Intervention: Neurodynamic sliders with static stretching (NS-SS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neurodynamic tensioners with static stretching (NT-SS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Static stretching alone (SS)
Number of subjects: 60
Study: 25393812

Group type: EXPERIMENTAL
Intervention: Independent daily stress
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dependent daily stress
Number of subjects: 138
Study: 23290219

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) + basic fibroblast growth factor (bFGF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT) alone
Number of subjects: 48
Study: 20942911

Group type: EXPERIMENTAL
Intervention: Moderate‐to‐high intensity Nordic Walking (NW)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Supervised low‐intensity walking (LIW)
Number of subjects: 67
Study: 16990449

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (OF-IN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve Yakult
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Synbiotic L. casei Shirota + OF-IN
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10672149

Group type: EXPERIMENTAL
Intervention: Titanium-base dentures
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resin-base dentures
Number of subjects: 25
Study: 9090338

Group type: EXPERIMENTAL
Intervention: Clinician-facilitated intervention (6 to 10 sessions)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lecture intervention (2 lectures attended only by parents)
Number of subjects: 37
Study: 1443508

Group type: EXPERIMENTAL
Intervention: Racemic ketamine (2 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (1 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both racemic ketamine and S(+)‐ketamine
Number of subjects: 10
Study: 3513810

Group type: EXPERIMENTAL
Intervention: Plain-tablets (2.5 mg terbutaline sulphate, three times daily at 6 h intervals)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Slow-release tablets (5 mg terbutaline sulphate, every 12 h)
Number of subjects: 10
Study: 31644933

Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 16
Study: 30559336

Group type: EXPERIMENTAL
Intervention: PASP <35 mmHg
Number of subjects: 363

Group type: COMPARATOR
Intervention: PASP ≥35 mmHg
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Time on dialysis
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Graft failure
Number of subjects: 363
Study: 27425582

Group type: EXPERIMENTAL
Intervention: External beam conformal radiotherapy
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Quality assurance processes
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Adherence to dose constraints in ProtecT
Number of subjects: 545
Study: 24595567

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg BID
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 23273255

Group type: EXPERIMENTAL
Intervention: High intensity isokinetic knee extensor resistance training (RT) for 8 weeks
Number of subjects: 64
Study: 20420799

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 30
Study: 17196547

Group type: EXPERIMENTAL
Intervention: Debriefed group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-debriefed group (control)
Number of subjects: 64
Study: 15886669

Group type: EXPERIMENTAL
Intervention: SIS wound matrix plus compression therapy (n = 62)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Compression therapy alone (n = 58)
Number of subjects: 120
Study: 12629231

Group type: EXPERIMENTAL
Intervention: GPi stimulation on
Number of subjects: 9

Group type: COMPARATOR
Intervention: GPi stimulation off (15 to 120 minutes)
Number of subjects: 9

Group type: COMPARATOR
Intervention: GPi stimulation off
Number of subjects: 9
Study: 10320164

Group type: EXPERIMENTAL
Intervention: IV ketoprofen
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 54
Study: 8919739

Group type: EXPERIMENTAL
Intervention: Self-inserted vaginal tampons
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clinician-obtained endocervical swabs
Number of subjects: 69
Study: 1862733

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 30918350

Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (butyrate and propionate)
Number of subjects: 0
Study: 27905255

Group type: EXPERIMENTAL
Intervention: Narrative self-reflection
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ruminative brooding
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Increased self-criticism
Number of subjects: 56
Study: 25872934

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 240
Study: 24035611

Group type: EXPERIMENTAL
Intervention: Sevoflurane induction with 8% for 2 minutes then 2.5%
Number of subjects: 34

Group type: COMPARATOR
Intervention: Target-controlled inhalation with a target end-tidal concentration of sevoflurane set at 2.5%
Number of subjects: 34
Study: 21862911

Group type: EXPERIMENTAL
Intervention: Stereophotogrammetry (SP)
Number of subjects: 10
Study: 19132881

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nortriptyline and Sertraline
Number of subjects: 27
Study: 17568956

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent assessment (Months 1-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent assessment (Months 7-12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No reactivity effects
Number of subjects: 0
Study: 16137089

Group type: EXPERIMENTAL
Intervention: Directly loaded Brånemark System or Replace Select Tapered implants (Nobel Biocare AB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference group treated according to a two‐stage protocol
Number of subjects: 20
Study: 12097537

Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 119

Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 119
Study: 10430149

Group type: EXPERIMENTAL
Intervention: Orally administered sonographic contrast agent (200, 400, 600, 800, or 1000 ml)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Orally administered sonographic contrast agent
Number of subjects: 99
Study: 8538189

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at a dose of 0.25 gm/m2 per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Number of subjects: 0
Study: 2142578

Group type: EXPERIMENTAL
Intervention: 30 micrograms of ethinyl estradiol + 150 micrograms of desogestrel (Marvelon; n = 21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35 micrograms of ethinyl estradiol + 2 mg of cyproterone acetate (Diane-35; n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (Marvelon and Diane-35)
Number of subjects: 40
Study: 7011113

Group type: EXPERIMENTAL
Intervention: Reproterol (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reproterol (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31204499

Group type: EXPERIMENTAL
Intervention: Collective-efficacy enhanced intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard health education/walking group
Number of subjects: 86
Study: 30253043

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg once daily for 72 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27183922

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at FiO2: 0.125 (4200 m)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at FiO2: 0.115 (4800 m)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normobaric hypoxia at FiO2: 0.209 (SL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normobaric hypoxia at FiO2: 0.135 (3600 m)
Number of subjects: 8
Study: 27137142

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg every 8 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg every 8 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22855206

Group type: EXPERIMENTAL
Intervention: Taurine (TA) 1,000 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 21342154

Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 100
Study: 19661927

Group type: EXPERIMENTAL
Intervention: Added potassium and calcium to cooking salt (10 mmol of potassium and 10 mmol of calcium).
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Salt-restricted diet (50-100 mmol per person per day).
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 325
Study: 16770213

Group type: EXPERIMENTAL
Intervention: Insertion of a drain in the epidural space
Number of subjects: 50

Group type: COMPARATOR
Intervention: No insertion of a drain
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Insertion of a drain
Number of subjects: 50
Study: 15322526

Group type: EXPERIMENTAL
Intervention: Anti-amyloid strategies (including secretase inhibition, amyloid-beta aggregation inhibition, immunotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurotrophic or neuroprotective approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies based on epidemiological observation
Number of subjects: 0
Study: 11253857

Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone or sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylaxis administered selectively to high-risk patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of rate control and anticoagulation with cardioversion if AF persists
Number of subjects: 0
Study: 9141112

Group type: EXPERIMENTAL
Intervention: 1 mg budesonide b.i.d. from Aiolos nebulizer
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1 mg budesonide b.i.d. from Pari LL nebulizer
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both nebulizers
Number of subjects: 38
Study: 7835809

Group type: COMPARATOR
Intervention: Current screening modalities of CA 125 and transvaginal ultrasonography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trial participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Access to information and specialists
Number of subjects: 0
Study: 3432897

Group type: EXPERIMENTAL
Intervention: CIVETE technique (intravaginal culture of embryos)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classic technique (control group, not detailed)
Number of subjects: 100
Study: 30504515

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (200 μg or 300 μg)
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Verapamil (5 mg)
Number of subjects: 1706
Study: 26704612

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine candidate (TDV)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 25458886

Group type: EXPERIMENTAL
Intervention: 1-g/kg psyllium (n=12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1-g/kg MgSO4 (n=10)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of psyllium and MgSO4 (n=12)
Number of subjects: 34
Study: 23459131

Group type: EXPERIMENTAL
Intervention: 3D teaching presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D traditional lecture
Number of subjects: 0
Study: 19825504

Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/day)
Number of subjects: 2069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2069
Study: 18786302

Group type: EXPERIMENTAL
Intervention: Prasugrel (60-mg loading dose, 10-mg maintenance dose for 7 days) with ranitidine (150 mg twice daily)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600-mg loading dose, 75-mg maintenance dose for 7 days) with ranitidine (150 mg twice daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Prasugrel alone (without ranitidine)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Clopidogrel alone (without ranitidine)
Number of subjects: 47
Study: 16095423

Group type: EXPERIMENTAL
Intervention: Strength training plus balanced low-energy diet (900-1200 cal)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 82
Study: 11942372

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections of 0.05, 0.05 and 0.1 mmol/kg over a 20-min period
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine, 0.2 mmol/kg bodyweight administered as sequential injections
Number of subjects: 74
Study: 10026745

Group type: EXPERIMENTAL
Intervention: 1-day transurethral catheterization
Number of subjects: 126

Group type: COMPARATOR
Intervention: 5-day transurethral catheterization
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 1-day transurethral catheterization (after excluding low rectum carcinoma)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 5-day transurethral catheterization (after excluding low rectum carcinoma)
Number of subjects: 126
Study: 7747617

Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2282920

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg twice daily for 2 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7321834

Group type: EXPERIMENTAL
Intervention: 80% MVC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60% MVC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40% MVC
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1.00 MVC (non-fatigued state)
Number of subjects: 15
Study: 27792398

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention with grief intervention module (12 therapy sessions over six months)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 273
Study: 27738234

Group type: EXPERIMENTAL
Intervention: Multimodal approach including telephone contacts, screening for adverse sequelae, written information, home visits, review of goal achievement, and further referral to relevant health services.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard management as determined by the treating team (Control group).
Number of subjects: 110
Study: 25082808

Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 527

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 527
Study: 22083873

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2164
Study: 19577405

Group type: EXPERIMENTAL
Intervention: Monetary reinforcement for attendance ($25 to $30)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard treatment sessions (control)
Number of subjects: 175
Study: 18450989

Group type: EXPERIMENTAL
Intervention: 0.9 g/kg dietary protein intake
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.5 g/kg dietary protein intake
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both dietary groups
Number of subjects: 34
Study: 15811982

Group type: EXPERIMENTAL
Intervention: Usual care plus supervised aerobic exercise training for 35 minutes 3 times per week for 16 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Usual care plus weekly 1.5‐hour stress management training for 16 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 12529549

Group type: EXPERIMENTAL
Intervention: CD34(+) enrichment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unselected mononucleated cells
Number of subjects: 18

Group type: COMPARATOR
Intervention: Serum-free versus serum-dependent culture medium
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cytokine combinations including flt3 ligand
Number of subjects: 18
Study: 10949811

Group type: EXPERIMENTAL
Intervention: Hydrophilic, acrylic lens: Bausch&Lomb‐Hydroview
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hydrophobic, acrylic Alcon Acrysof MA60 lens
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (senile cataract patients)
Number of subjects: 57
Study: 8971254

Group type: EXPERIMENTAL
Intervention: Arm exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Leg exercise
Number of subjects: 8
Study: 1532896

Group type: COMPARATOR
Intervention: succinylcholine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 60
Study: 4072599

Group type: EXPERIMENTAL
Intervention: 2% prilocaine with 0.4% hyaluronic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.4% hyaluronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% prilocaine without hyaluronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine without hyaluronic acid
Number of subjects: 0
Study: 30324849

Group type: EXPERIMENTAL
Intervention: Combination oxycodone (5‐mg) and acetaminophen (325‐mg) tablets, 15 tablets prescribed
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Combination oxycodone (5‐mg) and acetaminophen (325‐mg) tablets
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 219
Study: 29538683

Group type: EXPERIMENTAL
Intervention: CBD-rich botanical extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26575158

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Baseline HADS-A
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Baseline HADS-D
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: End of therapy HADS-D
Number of subjects: 103
Study: 25642582

Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT-S)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard smoking cessation treatment (ST)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both treatments (BCT-S and ST)
Number of subjects: 49
Study: 25063191

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline levels
Number of subjects: 20
Study: 20470229

Group type: EXPERIMENTAL
Intervention: Inhaled insulin therapy
Number of subjects: 240
Study: 18360068

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (5 mg/day of enalapril or imidapril)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study: 15976965

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fibrinolysis alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP) in patients with Killip class III or IV
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fibrinolysis alone in patients with Killip class III or IV
Number of subjects: 57
Study: 12593493

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg once daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lovastatin 20 mg once daily
Number of subjects: 28
Study: 10593132

Group type: EXPERIMENTAL
Intervention: Neutral-coated Calcium Acetate (NCCaAc)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Enteric-coated Calcium Acetate (ECCaAc)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Phos-ex (Cablon, The Netherlands)
Number of subjects: 19